Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

Background. PD-1/PD-L1 inhibitors have made unprecedented progress in the treatment of cancer. Methods. A systemic search was conducted for randomized controlled trials that compared PD-1/PD-L1 inhibitor monotherapy or combination therapy with nonimmunotherapy. Hazard ratios (HRs) of overall surviva...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuhan Wei, Yongfu Li, Qi Du, Xinyi Peng, Jiangtao Jin, Hong Guo, Yongyan Li, Qin Li
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2020/5269787
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
by: Yu Chen, et al.
Published: (2023-01-01)

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
by: Xiaojun Yang, et al.
Published: (2022-01-01)

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
by: Huimin Zhao, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy
by: Akihiro Ohara, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
by: Fei Yang, et al.
Published: (2025-01-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
by: Sandy El Bitar, et al.
Published: (2018-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors
by: Linan Yin, et al.
Published: (2025-01-01)

Relationship between the ultrasound features of different molecular subtypes of breast cancer and positive PD-1/PD-L1 expression
by: Ruiqian Yan, et al.
Published: (2025-02-01)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
by: Solange Peters, et al.
Published: (2023-10-01)

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
by: Seok Jun Park, et al.
Published: (2025-01-01)

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
by: Monika Walankiewicz, et al.
Published: (2018-01-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy
by: Peng Li, et al.
Published: (2024-07-01)

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
by: Yuanyuan Wang, et al.
Published: (2025-02-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Molecular mechanisms and correlation of CMTM6 and PD-L1 inhibitors in colorectal cancer treatment
by: Liang Gao, et al.
Published: (2025-02-01)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
by: Diwakar Davar, et al.
Published: (2015-01-01)

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2024-10-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Therapeutic implications for the PD-1 axis in cerebrovascular injury
by: James Feghali, et al.
Published: (2025-01-01)

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
by: Tingting Zhang, et al.
Published: (2022-04-01)

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2025-01-01)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
by: Alfred Zippelius, et al.
Published: (2022-11-01)